ArticleCancer causes & control : CCC2015
PTEN expression in benign human endometrial tissue and cancer in relation to endometrial cancer risk factors.
Article in Cancer causes & control : CCC, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 37 citations in OpenAlex.
- Histopathological and immunohistochemical analyses do not indicate timing of prophylactic hysterectomy: a retrospective analysis of endometrial biopsies in Lynch syndrome carriers.Familial cancer · 2026Article
- The dysregulation of the immune microenvironment during endometrial intraepithelial neoplasia serves as a marker of endometrial carcinogenesis.Frontiers in immunology · 2026Review
- PTEN status on gonadotropin-releasing hormone (GnRH) metabolite, GnRH-(1-5), effects in endometrial cancer cell lines migration, & transcriptomic analysis of basal cell line and tumor gene expressions†.Biology of reproduction · 2025Article
- Obesity as a Catalyst for Endometrial Hyperplasia and Cancer Progression: A Narrative Review of Epidemiology, Molecular Pathways, and Prevention.Biomedicines · 2025Review
- Clinical and Histopathological Correlates of Endometrial Proliferative Lesions in Perimenopausal Women: A Retrospective Study with Internal Validation of a Risk Model.Clinics and practice · 2025Article
- ob/ob obese mice promote tumorigenesis of endometrial cancer associated with Pten deficiency.Endocrine-related cancer · 2025Article
- Somatic PTEN and ARID1A loss and endometriosis disease burden: a longitudinal study.Human reproduction (Oxford, England) · 2025Article
- Endometrial Atypical Hyperplasia and Risk of Endometrial Cancer.Diagnostics (Basel, Switzerland) · 2024Review
- PTEN mutations as predictive marker for the high-grade endometrial cancer development in slovak women.Physiological research · 2022Article
- Somatic Genomic Events in Endometriosis: Review of the Literature and Approach to Phenotyping.Reproductive sciences (Thousand Oaks, Calif.) · 2021Review
- Research Progress on the Mechanism Between Polycystic Ovary Syndrome and Abnormal Endometrium.Frontiers in physiology · 2021Review
- Investigating the expressions of miRNA-125b andInternational journal of reproductive biomedicine · 2020Article
- Diagnostic and prognostic value of HABP2 as a novel biomarker for endometrial cancer.Annals of translational medicine · 2020Article
- Identification of six candidate genes for endometrial carcinoma by bioinformatics analysis.World journal of surgical oncology · 2020Article
- Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers.Clinical and translational radiation oncology · 2020Article
- Long Noncoding RNA HOTAIR Promotes Endometrial Carcinoma Cell Proliferation by Binding to PTEN via the Activating Phosphatidylinositol 3-Kinase/Akt Signaling Pathway.Molecular and cellular biology · 2019Article
- Delayed endometrial decidualisation in polycystic ovary syndrome; the role of AR-MAGEA11.Journal of molecular medicine (Berlin, Germany) · 2019Article
- PTEN suppresses the inflammation, viability, and motility of AP-AR42J cells by activating the Wnt/β-catenin pathway.RSC advances · 2019Article
- Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence.Journal of the National Cancer Institute · 2017Article
- Clinicopathological and immunohistochemical characterization of papillary proliferation of the endometrium: A single institutional experience.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 3 countries.
Funding
Abstract
purposeClonal loss of PTEN expression occurs frequently in endometrial carcinoma and endometrial hyperplasia. Limited data from immunohistochemical studies suggest that PTEN-null appearing endometrial glands are detectable in women without pathologic abnormalities, but the relationship of PTEN expression to endometrial cancer risk factors has not been extensively explored. We evaluated relationships between endometrial cancer risk factors and loss of PTEN expression in a set of benign endometrial samples prospectively collected from women undergoing hysterectomy and in endometrial cancer tissues from a population-based case-control study.
methodsWe used a validated PTEN immunohistochemical assay to assess expression in epidemiological studies designed to assess benign endometrium [Benign Reproductive Tissue Evaluation Study (n = 73); Einstein Endometrium Study (n = 19)], and endometrial cancer [Polish Endometrial Cancer Study (n = 148)] tissues. Associations between endometrial cancer risk factors (collected via study-specific risk factor questionnaires) and PTEN expression in endometrial tissues were determined using Fisher's exact tests.
resultsPTEN loss was detected in 19% of benign endometrial tissues versus 55% in endometrial cancers. NSAID use was statistically significantly associated with PTEN loss in the benign endometrium (p = 0.02).
conclusionOur data demonstrate that PTEN loss is detectable in endometrial tissues that are benign and malignant, with substantially more frequent loss in endometrial cancer compared with benign endometrium. However, alterations in expression were unrelated to most risk factors in this analysis, except for the association with NSAID use, which may represent a chance finding or reverse causality among patients with endometriosis who may have PTEN pathway abnormalities in eutopic endometrium. Further evaluation of factors associated with PTEN loss and long-term follow-up of women with PTEN-null endometrial glands may be useful in understanding early events in endometrial carcinogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.